Search

Your search keyword '"Tung, Shui-Yi"' showing total 337 results
Start Over Author "Tung, Shui-Yi"
337 results on '"Tung, Shui-Yi"'

1. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan

Author

Tsai, Pei-Chien, Kuo, Hsing-Tao, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Peng, Cheng-Yuan, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Lin, Chun-Yen, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Tung, Shui-Yi, Tai, Chi-Ming, Lin, Chih-Wen, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Yeh, Ming-Lun, Huang, Chung-Feng, Hsieh, Meng-Hsuan, Huang, Jee-Fu, Dai, Chia-Yen, Chung, Wan-Long, Chen, Chi-Yi, and Yu, Ming-Lung

Published
2023
Full Text
View/download PDF

3. The Cerebral Protective Effect of Novel Erinacines from Hericium erinaceus Mycelium on In Vivo Mild Traumatic Brain Injury Animal Model and Primary Mixed Glial Cells via Nrf2-Dependent Pathways

Author

Lee, Kam-Fai, primary, Hsieh, Yung-Yu, additional, Tung, Shui-Yi, additional, Teng, Chih-Chuan, additional, Cheng, Kung-Chuan, additional, Hsieh, Meng-Chiao, additional, Huang, Cheng-Yi, additional, Lee, Ko-Chao, additional, Lee, Li-Ya, additional, Chen, Wan-Ping, additional, Chen, Chin-Chu, additional, and Kuo, Hsing-Chun, additional

Published
2024
Full Text
View/download PDF

4. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Author

Yeh, Ming-Lun, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Chen, Chi-Yi, Kuo, Hsing-Tao, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Tai, Chi‐Ming, Lin, Chih-Wen, Kao, Jia-Horng, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Lin, Chun-Yen, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Tung, Shui-Yi, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Huang, Chung-Feng, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Tsai, Pei-Chien, Peng, Cheng-Yuan, Liu, Chun-Jen, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

9. Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis

Author

Hsu, Wei-Fan, Chen, Chi-Yi, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Kuo, Hsing-Tao, Hung, Chao-Hung, Tung, Shui-Yi, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Lin, Chun-Yen, Yang, Chi-Chieh, Lo, Gin-Ho, Tai, Chi-Ming, Lin, Chih-Wen, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Tsai, Pei-Chien, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung, and Peng, Cheng-Yuan

Published
2020
Full Text
View/download PDF

10. Supplemental Figures S1-S17 from Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression

Author

Chang, Te-Sheng, primary, Wu, Yu-Chih, primary, Chi, Ching-Chi, primary, Su, Wei-Chi, primary, Chang, Pey-Jium, primary, Lee, Kam-Fai, primary, Tung, Tao-Hsin, primary, Wang, Jui, primary, Liu, Jun-Jen, primary, Tung, Shui-Yi, primary, Kuo, Liang-Mou, primary, Ho, Hong-Nerng, primary, Ling, Thai-Yen, primary, and Huang, Yen-Hua, primary

Published
2023
Full Text
View/download PDF

11. Supplemental Tables S1-S7 from Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression

Author

Chang, Te-Sheng, primary, Wu, Yu-Chih, primary, Chi, Ching-Chi, primary, Su, Wei-Chi, primary, Chang, Pey-Jium, primary, Lee, Kam-Fai, primary, Tung, Tao-Hsin, primary, Wang, Jui, primary, Liu, Jun-Jen, primary, Tung, Shui-Yi, primary, Kuo, Liang-Mou, primary, Ho, Hong-Nerng, primary, Ling, Thai-Yen, primary, and Huang, Yen-Hua, primary

Published
2023
Full Text
View/download PDF

12. Supplemental Materials and Methods from Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression

Author

Chang, Te-Sheng, primary, Wu, Yu-Chih, primary, Chi, Ching-Chi, primary, Su, Wei-Chi, primary, Chang, Pey-Jium, primary, Lee, Kam-Fai, primary, Tung, Tao-Hsin, primary, Wang, Jui, primary, Liu, Jun-Jen, primary, Tung, Shui-Yi, primary, Kuo, Liang-Mou, primary, Ho, Hong-Nerng, primary, Ling, Thai-Yen, primary, and Huang, Yen-Hua, primary

Published
2023
Full Text
View/download PDF

15. Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis

Author

Hsieh, Yung-Yu, primary, Chen, Wei-Ming, additional, Chang, Kao-Chi, additional, Chang, Te-Sheng, additional, Hung, Chao-Hung, additional, Yang, Yao-Hsu, additional, Tung, Shui-Yi, additional, Wei, Kuo-Liang, additional, Shen, Chen-Heng, additional, Wu, Cheng-Shyong, additional, Ding, Yuan-Jie, additional, Hu, Jing-Hong, additional, Huang, Yu-Ting, additional, Lin, Meng-Hung, additional, Lu, Chung-Kuang, additional, Lin, Yi-Hsiung, additional, and Lin, Ming-Shyan, additional

Published
2023
Full Text
View/download PDF

17. Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir‐velpatasvir

Author

Su, Pei‐Kai, primary, Chang, Te‐Sheng, additional, Tung, Shui‐Yi, additional, Wei, Kuo‐Liang, additional, Shen, Chien‐Heng, additional, Hsieh, Yung‐Yu, additional, Chen, Wei‐Ming, additional, Chen, Yi‐Hsing, additional, Chen, Chun‐Hsien, additional, Yen, Chih‐Wei, additional, Xu, Huang‐Wei, additional, Tung, Wei‐Ling, additional, and Chang, Kao‐Chi, additional

Published
2022
Full Text
View/download PDF

20. Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study

Author

Wang, Hung-Wei, Tsai, Pei-Chein, Chen, Chi-Yi, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Kuo, Hsing-Tao, Hung, Chao-Hung, Tung, Shui-Yi, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Ron-Nan, Lin, Chun-Yen, Yang, Chi-Chieh, Lo, Gin-Ho, Tai, Chi-Ming, Lin, Chih-Wen, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung, and Peng, Cheng-Yuan

Subjects
Original Article
Abstract

A total of 1,589 patients who had received interferon-based treatment were enrolled and analyzed for the risk of hepatocellular carcinoma (HCC) in a real-world nationwide Taiwanese chronic hepatitis C cohort (T-COACH). We aimed to stratify HCC risk by non-invasive fibrosis index-based risk model. Of 1589 patients, 1363 (85.8%) patients achieved sustained virological response (SVR). Patients with SVR had 1, 3, 5 and 10-year cumulative HCC incidence rates of 0.55%, 1.87%, 3.48% and 8.35%, respectively. A Cox proportional hazards model revealed that non-SVR (adjusted hazard ratio [aHR]: 1.92, 95% confidence interval [CI]: 1.19-3.12, p = 0.008), diabetes mellitus (aHR: 2.11, 95% CI: 1.25-3.55, p = 0.005), and fibrosis (FIB)-4 at the end of follow-up (EOF; aHR: 5.60, 95% CI: 2.97-10.57, p < 0.0001) were independent predictors of HCC. Risk score models based on the three predictors were developed to predict HCC according to aHR. In model 1, the 10-year cumulative incidence rates of HCC were 43.35% in patients at high risk (score 9-10), 25.48% in those at intermediate risk (score 6-8), and 4.06% in those at low risk (score 3-5) of HCC. In model 2, the 10-year cumulative incidence rates of HCC were 39.64% in patients at high risk (at least two risk predictors), 19.12% in those at intermediate risk (with one risk predictor), and 2.52% in those at low risk (without any risk predictors) of HCC. The FIB-4-based prediction model at EOF could help stratify the risk of HCC in patients with chronic hepatitis C after antiviral treatment.

Published
2022

21. Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir‐velpatasvir

Author

Su, Pei‐Kai, Chang, Te‐Sheng, Tung, Shui‐Yi, Wei, Kuo‐Liang, Shen, Chien‐Heng, Hsieh, Yung‐Yu, Chen, Wei‐Ming, Chen, Yi‐Hsing, Chen, Chun‐Hsien, Yen, Chih‐Wei, Xu, Huang‐Wei, Tung, Wei‐Ling, and Chang, Kao‐Chi

Abstract

Direct‐acting antivirals (DAAs) have become an effective first‐line treatment for chronic hepatitis C (CHC), and the fixed‐dose combination of sofosbuvir (SOF) and velpatasvir (VEL) is one of the most important pangenotypic DAA regimen according to present treatment guideline. The association between SOF‐based regimens and renal toxicity remains controversial. A total of 953 patients including 130 with estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73m2and 823 with eGFR > 60 mL/min/1.73m2receiving SOF/VEL therapy for 12 weeks were enrolled in this study. The eGFR was assessed at baseline, end of treatment (EOT), and 12 weeks after completion of the therapy (end of follow‐up, EOF). The eGFR in patients with eGFR ≤ 60 mL/min/1.73m2increased from baseline (47.89 ± 10.25 mL/min/1.73m2) to EOT (51.65 ± 15.92; P< .001) and EOF (51.51 ± 14.46 mL/min/1.73m2; P< .05). The eGFR in patients with eGFR > 60 mL/min/1.73m2at baseline (91.52 ± 22.06 mL/min/1.73m2) was lower at EOT (90.37 ± 22.3; P< .05), with no difference between EOT and EOF (P= .06). Multivariable analysis showed that a higher serum albumin level was associated with a lower risk of eGFR decrease at EOT, and the patients with baseline eGFR > 60 mL/min/1.73m2were associated with a higher risk of eGFR decrease at EOF. The rates of sustained virologic response 12 weeks after treatment cessation (SVR12) were 99.2% in per‐protocol analysis, and the most common adverse events were fatigue (4.7%), abdominal discomfort (4.5%), and skin itching (3.7%). In conclusion, renal function improved after the SOF/VEL treatment in patients with CHC and chronic kidney disease. Thus, SOF/VEL was safe, effective, and tolerable in these patients.

Published
2023
Full Text
View/download PDF

22. Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting

Author

Lu, Yung-Hsin, primary, Lu, Chung-Kuang, additional, Chen, Chun-Hsien, additional, Hsieh, Yung-Yu, additional, Tung, Shui-Yi, additional, Chen, Yi-Hsing, additional, Yen, Chih-Wei, additional, Tung, Wei-Lin, additional, Chang, Kao-Chi, additional, Chen, Wei-Ming, additional, Lu, Sheng-Nan, additional, Hung, Chao-Hung, additional, and Chang, Te-Sheng, additional

Published
2022
Full Text
View/download PDF

25. HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses

Author

Yu, Ming-Lung, Lee, Chuan-Mo, Chuang, Wan-Long, Lu, Sheng-Nan, Dai, Chia-Yen, Huang, Jee-Fu, Lin, Zu-Yau, Hu, Tsung-Hui, Chen, Chien-Hung, Hung, Chao-Hung, Wang, Jin-Houng, Chen, Chi-Ling, Kao, Jia-Horng, Lai, Ming-Yang, Liu, Chen-Hua, Su, Tung-Hung, Wu, Shun-Sheng, Liao, Li-Ying, Kuo, Hsing-Tao, Chao, You-Chen, Tung, Shui-Yi, Yang, Sien-Sing, Chen, Pei-Jer, Liu, Chun-Jen, and Chen, Ding-Shinn

Published
2010

27. The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir

Author

Wu, Cheng-Kun, primary, Chen, Li-Wei, additional, Chang, Te-Sheng, additional, Tung, Shui-Yi, additional, Lin, Chun-Yen, additional, Hung, Chao-Hung, additional, Lu, Sheng-Nan, additional, Lin, Chih-Lang, additional, Chen, Chien-Hung, additional, Hsu, Chao-Wei, additional, Hu, Tsung-Hui, additional, and Sheen, I-Shyan, additional

Published
2022
Full Text
View/download PDF

28. Fusobacterium Nucleatum-Induced Tumor Mutation Burden Predicts Poor Survival of Gastric Cancer Patients.

Author

Hsieh, Yung-Yu, Kuo, Wen-Lin, Hsu, Wan-Ting, Tung, Shui-Yi, and Li, Chin

Subjects
STOMACH tumors, DISEASE progression, BIOMARKERS, GENETIC mutation, HELICOBACTER pylori, GUT microbiome, CANCER patients, MIXED infections, RESEARCH funding, BACTERIAL diseases, FUSOBACTERIUM, OVERALL survival
Abstract

Simple Summary: Gastric cancer is the fifth most common cancer in the world. An important risk factor in the development of alimentary tract cancers is the presence of pathogenic microbiota, such as Helicobacter pylori. We previously showed that sporadic infection of Fusobacterium nucleatum is associated with disease progression. Therefore, we examined the mutational landscape of F. nucleatum-positive, resected gastric cancer tissues using the Illumina TruSight Oncology 500 comprehensive panel to identify small nucleotide variants, small insertions and deletions, and unstable microsatellite sites. We identified a number of recurrent genetic aberrations, especially activating mutations of ERBB2, ERBB3, and PIK3CA and disrupted TP53. We found that the combination of F. nucleatum infection and high tumor mutational burden was a strong predictor of poor prognosis. Thus, F. nucleatum infection is correlated with increased accumulation of mutations and progression of gastric cancer, and these factors may be useful in the prognosis of this disease. Co-infection of Helicobacter pylori and Fusobacterium nucleatum is a microbial biomarker for poor prognosis of gastric cancer patients. Fusobacterium nucleatum is associated with microsatellite instability and the accumulation of mutations in colorectal cancer. Here, we investigated the mutation landscape of Fusobacterium nucleatum-positive resected gastric cancer tissues using Illumina TruSight Oncology 500 comprehensive panel. Sequencing data were processed to identify the small nucleotide variants, small insertions and deletions, and unstable microsatellite sites. The bioinformatic algorithm also calculated copy number gains of preselected genes and tumor mutation burden. The recurrent genetic aberrations were identified in this study cohort. For gene amplification events, ERBB2, cell cycle regulators, and specific FGF ligands and receptors were the most frequently amplified genes. Pathogenic activation mutations of ERBB2, ERBB3, and PIK3CA, as well as loss-of-function of TP53, were identified in multiple patients. Furthermore, Fusobacterium nucleatum infection is positively correlated with a higher tumor mutation burden. Survival analysis showed that the combination of Fusobacterium nucleatum infection and high tumor mutation burden formed an extremely effective biomarker to predict poor prognosis. Our results indicated that the ERBB2-PIK3-AKT-mTOR pathway is frequently activated in gastric cancer and that Fusobacterium nucleatum and high mutation burden are strong biomarkers of poor prognosis for gastric cancer patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Identification of Two Novel CIL-102 Upregulations of ERP29 and FUMH to Inhibit the Migration and Invasiveness of Colorectal Cancer Cells by Using the Proteomic Approach

Author

Cheng, Kung-Chuan, primary, Kuo, Hsing-Chun, additional, Hsieh, Meng-Chiao, additional, Huang, Cheng-Yi, additional, Teng, Chih-Chuan, additional, Tung, Shui-Yi, additional, Shen, Chien-Heng, additional, Lee, Kam-Fai, additional, Yang, Ya-Ling, additional, and Lee, Ko-Chao, additional

Published
2021
Full Text
View/download PDF

33. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis‐related complications (Taiwanese chronic hepatitis C cohort)

Author

Hsu, Wei‐Fan, primary, Tsai, Pei‐Chein, additional, Chen, Chi‐Yi, additional, Tseng, Kuo‐Chih, additional, Lai, Hsueh‐Chou, additional, Kuo, Hsing‐Tao, additional, Hung, Chao‐Hung, additional, Tung, Shui‐Yi, additional, Wang, Jing‐Houng, additional, Chen, Jyh‐Jou, additional, Lee, Pei‐Lun, additional, Chien, Ron‐Nan, additional, Lin, Chun‐Yen, additional, Yang, Chi‐Chieh, additional, Lo, Gin‐Ho, additional, Tai, Chi‐Ming, additional, Lin, Chih‐Wen, additional, Kao, Jia‐Horng, additional, Liu, Chun‐Jen, additional, Liu, Chen‐Hua, additional, Yan, Sheng‐Lei, additional, Bair, Ming‐Jong, additional, Su, Wei‐Wen, additional, Chu, Cheng‐Hsin, additional, Chen, Chih‐Jen, additional, Lo, Ching‐Chu, additional, Cheng, Pin‐Nan, additional, Chiu, Yen‐Cheng, additional, Wang, Chia‐Chi, additional, Cheng, Jin‐Shiung, additional, Tsai, Wei‐Lun, additional, Lin, Han‐Chieh, additional, Huang, Yi‐Hsiang, additional, Huang, Jee‐Fu, additional, Dai, Chia‐Yen, additional, Chuang, Wan‐Long, additional, Yu, Ming‐Lung, additional, and Peng, Cheng‐Yuan, additional

Published
2021
Full Text
View/download PDF

34. Pangenotypic direct‐acting antiviral agents for mixed genotype hepatitis C infection: A real‐world effectiveness analysis

Author

Ding, Yuan‐Jie, primary, Lu, Chung‐Kuang, additional, Chen, Wei‐Ming, additional, Tung, Shui‐Yi, additional, Wei, Kuo‐Liang, additional, Shen, Chen‐Heng, additional, Hsieh, Yung‐Yu, additional, Yen, Chih‐Wei, additional, Chang, Kao‐Chi, additional, Chiu, Wen‐Nan, additional, Hung, Chao‐Hung, additional, Lu, Sheng‐Nan, additional, and Chang, Te‐Sheng, additional

Published
2021
Full Text
View/download PDF

36. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection in Taiwan

Author

Chang, Kao-Chi, primary, Tung, Shui-Yi, additional, Wei, Kuo-Liang, additional, Shen, Chen-Heng, additional, Hsieh, Yung-Yu, additional, Chen, Wei-Ming, additional, Chen, Yi-Hsing, additional, Chen, Chun-Hsien, additional, Yen, Chi-Wei, additional, Xu, Huang-Wei, additional, Tung, Wei-Lin, additional, Hung, Chao-Hung, additional, Lu, Sheng-Nan, additional, and Chang, Te-Sheng, additional

Published
2021
Full Text
View/download PDF

37. Apoptotic mechanisms of gastric cancer cells induced by isolated erinacine S through epigenetic histone H3 methylation of FasL and TRAIL

Author

Tung, Shui-Yi, primary, Lee, Ko-Chao, additional, Lee, Kam-Fai, additional, Yang, Ya-Ling, additional, Huang, Wen-Shih, additional, Lee, Li-Ya, additional, Chen, Wan-Ping, additional, Chen, Chin-Chu, additional, Teng, Chih-Chuan, additional, Shen, Chien-Heng, additional, Hsieh, Meng-Chiao, additional, Huang, Cheng-Yi, additional, Sheen, Jiunn-Ming, additional, and Kuo, Hsing-Chun, additional

Published
2021
Full Text
View/download PDF

40. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

Author

Yu, Ming-Lung, Lee, Chuan-Mo, Chen, Chi-Ling, Chuang, Wan-Long, Lu, Sheng-Nan, Liu, Chen-Hua, Wu, Shun-Sheng, Liao, Li-Ying, Kuo, Hsing-Tao, Chao, You-Chen, Tung, Shui-Yi, Yang, Sien-Sing, Kao, Jia-Horng, Su, Wei-Wen, Lin, Chih-Lin, Yang, Hung-Chih, Chen, Pei-Jer, Chen, Ding-Shinn, and Liu, Chun-Jen

Published
2013
Full Text
View/download PDF

43. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy

Author

Chen, Wei-Ming, primary, Wei, Kuo-Liang, additional, Tung, Shui-Yi, additional, Shen, Chien-Heng, additional, Chang, Te-Sheng, additional, Yen, Chih-Wei, additional, Hsieh, Yung-Yu, additional, Chiu, Wen Nan, additional, Hu, Jin Hung, additional, Lu, Sheng-Nan, additional, and Hung, Chao-Hung, additional

Published
2020
Full Text
View/download PDF

44. Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH)

Author

Tsai, Pei-Chien, primary, Chen, Chi-Yi, additional, Kuo, Hsing-Tao, additional, Hung, Chao-Hung, additional, Tseng, Kuo-Chih, additional, Lai, Hsueh-Chou, additional, Peng, Cheng-Yuan, additional, Wang, Jing-Houng, additional, Chen, Jyh-Jou, additional, Lee, Pei-Lun, additional, Chien, Rong-Nan, additional, Yang, Chi-Chieh, additional, Lo, Gin-Ho, additional, Kao, Jia-Horng, additional, Liu, Chun-Jen, additional, Liu, Chen-Hua, additional, Yan, Sheng-Lei, additional, Bair, Ming-Jong, additional, Lin, Chun-Yen, additional, Su, Wei-Wen, additional, Chu, Cheng-Hsin, additional, Chen, Chih-Jen, additional, Tung, Shui-Yi, additional, Tai, Chi-Ming, additional, Lin, Chih-Wen, additional, Lo, Ching-Chu, additional, Cheng, Pin-Nan, additional, Chiu, Yen-Cheng, additional, Wang, Chia-Chi, additional, Cheng, Jin-Shiung, additional, Tsai, Wei-Lun, additional, Lin, Han-Chieh, additional, Huang, Yi-Hsiang, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Hsieh, Meng-Hsuan, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chung, Wan-Long, additional, Ke, Chiao-Li Khale, additional, and Yu, Ming-Lung, additional

Published
2020
Full Text
View/download PDF

46. Real‐world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan

Author

Chiu, Wen‐Nan, primary, Hung, Chao‐Hung, additional, Lu, Sheng‐Nan, additional, Chen, Mei‐Yen, additional, Tung, Shui‐Yi, additional, Wei, Kuo‐Liang, additional, Lu, Chung‐Kuang, additional, Chen, Chien‐Hung, additional, Hu, Tsung‐Hui, additional, Hu, Jin‐Hung, additional, Chen, Wei‐Ming, additional, and Chang, Te‐Sheng, additional

Published
2020
Full Text
View/download PDF

48. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Author

Huang, Chung-Feng, primary, Lai, Hsueh-Chou, additional, Chen, Chi-Yi, additional, Tseng, Kuo-Chih, additional, Kuo, Hsing-Tao, additional, Hung, Chao-Hung, additional, Wang, Jing-Houng, additional, Chen, Jyh-Jou, additional, Lee, Pei-Lun, additional, Chien, Rong-Nan, additional, Yang, Chi-Chieh, additional, Lo, Gin-Ho, additional, Tai, Chi-Ming, additional, Lin, Chih-Wen, additional, Kao, Jia-Horng, additional, Liu, Chun-Jen, additional, Liu, Chen-Hua, additional, Yan, Sheng-Lei, additional, Bair, Ming-Jong, additional, Lin, Chun-Yen, additional, Su, Wei-Wen, additional, Chu, Cheng-Hsin, additional, Chen, Chih-Jen, additional, Tung, Shui-Yi, additional, Lo, Ching-Chu, additional, Cheng, Pin-Nan, additional, Chiu, Yen-Cheng, additional, Wang, Chia-Chi, additional, Cheng, Jin-Shiung, additional, Tsai, Wei-Lun, additional, Lin, Han-Chieh, additional, Huang, Yi-Hsiang, additional, Yeh, Ming-Lun, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, Tsai, Pei-Chien, additional, Peng, Cheng-Yuan, additional, and Yu, Ming-Lung, additional

Published
2020
Full Text
View/download PDF

49. Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C

Author

Lin, Sheng Feng, primary, Tung, Shui-Yi, additional, Wei, Kuo-Liang, additional, Chen, Chien-Hung, additional, Hu, Tsung-Hui, additional, Shen, Chien Heng, additional, Chang, Te-Sheng, additional, Chen, Wei-Ming, additional, Yen, Chih-Wei, additional, Wang, Jing-Houng, additional, Hung, Chao-Hung, additional, and Lu, Sheng-Nan, additional

Published
2020
Full Text
View/download PDF

50. Limited effects of antibiotic prophylaxis in patients with Child–Pugh class A/B cirrhosis and upper gastrointestinal bleeding

Author

Chang, Te-Sheng, primary, Tsai, Ying-Huang, additional, Lin, Yi-Heng, additional, Chen, Chun-Hsien, additional, Lu, Chung-Kuang, additional, Huang, Wen-Shih, additional, Yang, Yao-Hsu, additional, Chen, Wei-Ming, additional, Hsieh, Yung-Yu, additional, Wu, Yu-Chih, additional, Tung, Shui-Yi, additional, and Huang, Yen-Hua, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results